Evidence map›Paper›PMID 27766186›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2016

Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma.

Maria Danielsen, Andreas Kjaer, Max Wu, Lea Martineau, Mehdi Nosrati, Stanley Pl Leong, Richard W Sagebiel, James R Miller, Mohammed Kashani-Sabet

Abstract read
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. PET and SPECT imaging of melanoma: the state of the art.European journal of nuclear medicine and molecular imaging · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Maria DanielsenCenter for Melanoma Research and Treatment, California Pacific Medical Center Research InstituteSan Francisco, California 95107, USA; University of CopenhagenCopenhagen, Denmark.
Andreas KjaerDepartment of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen Copenhagen, Denmark.
Max WuDepartment of Nuclear Medicine and Radiology, California Pacific Medical Center San Francisco, California 95107, USA.
Lea MartineauCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute San Francisco, California 95107, USA.
Mehdi NosratiCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute San Francisco, California 95107, USA.
Stanley Pl LeongCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute San Francisco, California 95107, USA.
Richard W SagebielCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute San Francisco, California 95107, USA.
James R MillerCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute San Francisco, California 95107, USA.
Mohammed Kashani-SabetCenter for Melanoma Research and Treatment, California Pacific Medical Center Research Institute San Francisco, California 95107, USA.
Rigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positron emission tomography/computed tomography (PET/CT) is an important tool to identify occult melanoma metastasis. To date, it is controversial which patients with primary cutaneous melanoma should have staging PET/CT. In this retrospective analysis of more than 800 consecutive patients with cutaneous melanoma, we sought to identify factors predictive of PET/CT positivity in the setting of newly-diagnosed high-risk primary melanoma to determine those patients most appropriate to undergo a PET/CT scan as part of their diagnostic work up. 167 patients with newly-diagnosed high-risk primary cutaneous melanoma underwent a PET/CT scan performed as part of their initial staging. Clinical and histologic factors were evaluated as possible predictors of melanoma metastasis identified on PET/CT scanning using both univariate and multivariate logistic regression. In all, 32 patients (19.2%) had a positive PET/CT finding of metastatic melanoma. In more than half of these patients (56.3%), PET/CT scanning identified disease that was not detectable on clinical examination. Mitotic rate, tumor thickness, lymphadenopathy, and bleeding were significantly predictive of PET/CT positivity. A combinatorial index constructed from these factors revealed a significant association between number of high-risk factors observed and prevalence of PET/CT positivity, which increased from 5.8% (with the presence of 0-2 factors) to 100.0%, when all four factors were present. These results indicate that combining clinical and histologic prognostic factors enables the identification of patients with a higher likelihood of a positive PET/CT scan.

Indexed as

FDGMelanomamolecular imagingnuclear medicinePETPET/CTskin cancerstaging

Identifiers

PMID27766186
PMCPMC5069280
OpenAlexW2544801325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.